Baird Maintains Neutral on Sage Therapeutics, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Joel Beatty maintains a Neutral rating on Sage Therapeutics (NASDAQ:SAGE) and keeps the price target at $15.
June 11, 2024 | 12:39 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Baird analyst Joel Beatty maintains a Neutral rating on Sage Therapeutics and keeps the price target at $15.
The analyst's neutral rating and maintained price target suggest no immediate change in the stock's outlook. This is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 100
IMPORTANCE 50
RELEVANCE 100